Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
Holding ORIC?
Track your performance easily

Oric Pharmaceuticals (ORIC) Income Statement

293 Followers

Oric Pharmaceuticals Income Statement

Last quarter (Q2 2024), Oric Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Oric Pharmaceuticals's net income was $-31.96M. See Oric Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 125.12M$ 110.78M$ 91.77M$ 78.87M$ 49.34M$ 28.57M
Operating Income
$ -125.12M$ -110.78M$ -91.77M$ -78.87M$ -49.34M$ -28.57M
Net Non Operating Interest Income Expense
$ -1.73M-$ 2.65M$ 141.00K$ 306.00K$ 1.40M
Other Income Expense
$ -16.07M$ 10.08M-$ -15.00K$ -24.67M$ 289.00K
Pretax Income
$ -110.78M$ -100.70M$ -89.12M$ -78.72M$ -73.70M$ -26.88M
Tax Provision
$ -6.93M$ -6.93M$ -6.00M$ -30.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -110.78M$ -100.70M$ -89.12M$ -78.72M$ -73.70M$ -26.88M
Basic EPS
$ -1.75$ -1.96$ -2.25$ -2.07$ -3.36$ -1.40
Diluted EPS
$ -1.75$ -1.96$ -2.25$ -2.07$ -3.36$ -1.40
Basic Average Shares
$ 252.76M$ 51.45M$ 39.66M$ 37.95M$ 21.94M$ 19.14M
Diluted Average Shares
$ 252.76M$ 51.45M$ 39.66M$ 37.95M$ 21.94M$ 19.14M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 125.12M$ 110.78M$ 91.77M$ 78.87M$ 49.34M$ 28.57M
Net Income From Continuing And Discontinued Operation
$ -110.78M$ -100.70M$ -89.12M$ -78.72M$ -73.70M$ -26.88M
Normalized Income
$ -87.04M$ -107.63M$ -95.13M-$ -48.86M$ -26.88M
Interest Expense
------
EBIT
$ -117.86M$ -110.78M$ -89.12M$ -78.72M$ -49.34M$ -28.57M
EBITDA
$ -116.50M$ -109.75M$ -89.16M$ -76.47M$ -48.37M$ -27.54M
Currency in USD

Oric Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis